The Jenex Corporation Announces Completion of Debt Settlement, Files TherOZap(TM) Device Patent and Presents at Chinese Global Financial Forum
Toronto, Ontario--(Newsfile Corp. - December 4, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announces that has received both shareholder and NEX Exchange approval and accordingly has closed its debt settlement arrangements with certain insiders and former insiders of the Company and issued an aggregate of 16,008,634 common shares at a deemed price of $0.05/share to settle and extinguish an aggregate of...
2017-12-04 9:23 AM EST
The Jenex Corporation Announces AGM Results and Submits Application to Graduate to TSXV
Toronto, Ontario--(Newsfile Corp. - November 23, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, would like to announce the voting results from its Annual General and Special Meeting of shareholders (the "Meeting") held last week in Toronto, Ontario on November 15, 2017. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 10,439,138, representing 41.26% of the...
2017-11-23 8:46 AM EST
The Jenex Corporation Signs Letter of Intent to Acquire Medical Device Assets
Toronto, Ontario--(Newsfile Corp. - November 2, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announces that it has entered into a non-binding letter of intent ("LOI" or the "Proposed Acquisition") for two medical device products with established sales and cash flow (the "Acquisition Targets"). The Acquisition Targets have been sold worldwide under established brand names. The Acquisition Targets utilize thermal...
2017-11-02 8:00 AM EDT
IIROC Trade Resumption - The Jenex Corporation
Vancouver, British Columbia--(Newsfile Corp. - October 12, 2017) - Trading resumes in: Company: The Jenex Corporation
2017-10-12 1:18 PM EDT
The Jenex Corporation Reports Promising Initial Results on Zika Virus Testing with TherOZap(TM)
Toronto, Ontario--(Newsfile Corp. - October 12, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announces that it has received promising initial results on the Zika virus testing with TherOZap™. Dr. Alyson Kelvin at UHN reported the following: "To evaluate the effectiveness of the Jenex TherOZap™ device against the infectivity of Zika virus, cells were infected with a range of Zika virus doses and treated with the...
2017-10-12 1:12 PM EDT
IIROC Trade Halt - The Jenex Corporation
Vancouver, British Columbia--(Newsfile Corp. - October 11, 2017) - The following issues have been halted by IIROC: Company:
2017-10-11 9:12 AM EDT
The Jenex Corporation Announces Grant of Stock Options
Toronto, Ontario--(Newsfile Corp. - October 6, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"). Jenex would like to announce the grant of stock options to directors, officers and consultants of the Company to purchase up to an aggregate of 1,500,000 common shares of the Company pursuant to the Company's share option plan. The options are exercisable for a period of five years at a price of $0.11/share. About Jenex: Jenex is a progressive medical device technology...
2017-10-06 6:19 PM EDT
The Jenex Corporation Terminates Exclusive License Agreement with Luminar Media Group Inc.
Toronto, Ontario--(Newsfile Corp. - October 2, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announced that it has formally terminated its exclusive agreement dated October 31st, 2016 to distribute TherOZap™ globally outside of Canada (the "Agreement") with Luminar Media Group Inc. ("Luminar"), for reasons of non-performance of fees payable as outlined in the Agreement. Jenex may in the future consider a...
2017-10-02 5:33 PM EDT
The Jenex Corporation Announces Approvals of Equity Financing & Move to TSX Venture Exchange (TSXV)
Toronto, Ontario--(Newsfile Corp. - September 19, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"), a progressive medical device technology company, today announced that it has completed a non-brokered private placement (the "Private Placement Financing") of 6,350,000 Units ("Units") of the Company at a price of $0.05 per Unit for gross proceeds of $317,500 and has received final stock exchange approval therefor. The Units were oversubscribed and approval was granted...
2017-09-19 8:00 AM EDT
Jenex Reports Expected Date of Test Results for TherOZap(TM) at Inactivating the Zika Virus
Toronto, Ontario--(Newsfile Corp. - September 14, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"), a progressive medical device technology company, would like to report that the Techna Institute at UHN has informed Jenex that the initial data results for TherOZap™ at inactivating the Zika virus are expected to be received during the week of October 2nd with an outside reporting date during the second week of October. Techna Institute has informed Jenex that additional...
2017-09-14 4:30 PM EDT
Jenex is Unaware of Any Material Change
Toronto, Ontario--(Newsfile Corp. - August 30, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"). At the request of IIROC, The Jenex Corporation wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. About Jenex: Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their...
2017-08-30 12:56 PM EDT
The Jenex Corporation Announces Conditional Acceptance of Reactivation from NEX to TSX Venture Exchange, TherOZap(TM) Testing and ISO 13485:2003 Update
Toronto, Ontario--(Newsfile Corp. - August 17, 2017) - The Jenex Corporation (NEX: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announces that it has obtained the conditional acceptance of the TSX Venture Exchange (the "Exchange" or "TSXV") in respect of its application for reactivation to the TSXV as a Tier 2 Life Science Issuer (the "Graduation"). The Graduation is conditional upon satisfaction of the following conditions on or before November...
2017-08-17 8:57 AM EDT
The Jenex Corporation Completes $317,500 Oversubscribed Non-Brokered Private Placement with Insider Participation
Toronto, Ontario--(Newsfile Corp. - June 21, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, is pleased to announce that further to its May 29, 2017 announcement, (The Jenex Corporation Announces Equity Financing with Insider Participation), it has completed, subject to receiving final acceptance from the TSX Venture Exchange (the "TSXV"), an oversubscribed non-brokered private placement (the "Financing") of 6,350,000...
2017-06-21 4:26 PM EDT
The Jenex Corporation Announces Equity Financing with Insider Participation
Toronto, Ontario--(Newsfile Corp. - May 29, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announced that it intends to complete a non-brokered private placement (the "Private Placement Financing") of up to 5,000,000 units ("Units") of the Company at a price of $0.05 per Unit for gross proceeds of up to $250,000 subject to regulatory and stock exchange approval. There is no minimum offering amount. Each Unit will...
2017-05-29 4:18 PM EDT
Jenex Finalizing Protocol to Test TherOZap(TM) Against the Zika Virus with University Health Network
Toronto, Ontario--(Newsfile Corp. - May 23, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, is pleased to report that after extensive collaboration with Techna Institute and University Health Network ("UHN"), the Company is now in the final stages of designing a testing protocol for the patent pending TherOZap™ device to determine its effectiveness at inactivating the Zika virus. Through this collaboration Jenex and UHN...
2017-05-23 7:00 AM EDT
Jenex to Test TherOZap(TM) Working Prototype and Topical Cannabidiol Oil Against the Zika and West Nile Viruses
Toronto, Ontario--(Newsfile Corp. - April 18, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, would like to report the testing of a topical cannabidiol ("CBD") oil from hemp with Jenex's platform technology, including Jenex's TherOZap™ device. The topical cannabidiol oil will be included in the lab tests, to be conducted through University Health Network and coordinated through Techna Institute at UHN located in Toronto,...
2017-04-18 9:17 AM EDT
Jenex Completes Design of TherOzap(TM) Working Prototype and Signs Service Agreement with University Health Network to Initiate Testing Against the Zika and West Nile Viruses
Toronto, Ontario--(Newsfile Corp. - April 7, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"), a progressive medical device technology company, would like to report that the design of the working prototype for the patent pending TherOZap™ is now complete. Images of the working prototype can be viewed here: www.therozap.com. Jenex has optimized the features on the TherOZap™ working prototype device to determine its effectiveness at inactivating both the Zika virus and...
2017-04-07 9:16 AM EDT
The Jenex Corporation Announces Shares For Debt Closing
Toronto, Ontario--(Newsfile Corp. - April 6, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company") announces that it has issued 18,341,302 common shares to settle $917,065 of debt owing by the Company. The shares are subject to a hold period which expires on August 6, 2017. This is the first of two closings of the debt settlement described in the Company's news release of February 13, 2017. The TSX Venture Exchange has approved the issuance of an additional 16,008,634 common...
2017-04-06 4:18 PM EDT
Jenex Provides Update on TherOZap(TM) Working Prototype, and InterceptCS
Toronto, Ontario--(Newsfile Corp. - March 6, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"). Jenex would like to report that the development of the working prototype for the patent pending TherOZap™ is scheduled for completion prior to the end of March 2017. The Company has finalized the optimal components and features for the working prototype. As previously reported Jenex expects to test the working prototype to determine its effectiveness at inactivating both the...
2017-03-06 8:20 AM EST
Jenex Unaware of Any Material Change
Toronto, Ontario--(Newsfile Corp. - February 27, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"). At the request of IIROC, The Jenex Corporation wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. About Jenex: Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their...
2017-02-27 2:18 PM EST